Fulgent Genetics Reports Results for Quarter Ended June 30, 2026

What Happened

• On July 30, 2026, Fulgent Genetics, Inc. announced its financial results for the fiscal quarter ended June 30, 2026 via a press release. The press release announcing those results is furnished as Exhibit 99.1 to the Form 8-K.
• The company also updated its investor presentation (furnished as Exhibit 99.2) and made it available on the Investor Relations site: http://ir.fulgentgenetics.com.
• The disclosure was furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure); the materials are furnished (not “filed”) and therefore are not subject to Section 18 liability or automatically incorporated by reference into other filings.

Key Details

• Date of disclosure: July 30, 2026.
• Reporting period: fiscal quarter ended June 30, 2026.
• Press release = Exhibit 99.1; updated investor presentation = Exhibit 99.2 (available on the company’s IR website).
• Form 8-K signed by Paul Kim, Chief Financial Officer.

Why It Matters

• This 8-K provides the company’s official quarterly results and updated investor materials, which are primary sources for assessing recent revenue, earnings, and operational performance.
• Investors should review the furnished press release and presentation on the IR site for the detailed figures and commentary; note these materials are furnished (not filed), which affects legal liabilities and incorporation by reference in other SEC filings.